FCF Life Sciences Venture Capital Monitor – Europe 01/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2022”.

The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of January 2022 we identify the following current VC trends in Europe:

  • The current funding for life sciences amounts to EUR 957m and is thus about EUR 400m below the previous year’s level
  • The top 5 deals are each above EUR 50m, the largest deal is above EUR 100m and took place in Germany (Patient21)
  • Target Global (Germany) ranks first among the top 5 investors (by deal volume), followed by Piton Capital (UK) and Eight Roads (USA)
  • 35% of total investment volume was placed in the biotech sector (+7% points month-on-month)
  • Infectious diseases is the indication with the highest investment activity in the biotech sector

To access the full report, please click here.

By Dr. Mathias Schott and Sebastian Sommer

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]